The fund will be used to pioneer a bone metastasis risk profiling platform for personalized treatment of breast cancer patients. To this end high-precision 3D-printed bone niches of various topographies will be used to interrogate their colonization by aggressive human breast cancer cells in vitro. The two-year project is coordinated by Cristiana Lungu (Olayioye group, IZI) and builds on the close collaboration with the teams of Marcel Hörning and Michael Heymann (IBBS).